AGN:CSE; AGNPF:OTCQB; AGW:FSE

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
AGN:CSE AGNPF:OTCQB AGW:FSE

Expert Comments:

Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure.
read more >
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about.
read more >
Algernon Pharmaceuticals reported expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021.
read more >
Algernon Pharmaceuticals aims to begin the study as soon as it receives the drug from the manufacturer.
read more >
headshot of André Uddin

André Uddin, Research Capital Corporation

(3/1/21)
"The database of the Phase 2b part of Algernon Pharmaceuticals Inc.'s Phase 2b/3 trial with ifenprodil in COVID-19 is to be locked for analysis on March 5, 2021; final results are expected to be disclosed shortly thereafter. Results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis/chronic cough are expected in Q2/21 or Q3/21 for early chronic cough data and Q4/21 for full study data."

Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol.
read more >
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients.
read more >
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report.
read more >

André Uddin, Research Capital Corporation

(2/2/21)
"Algernon Pharmaceuticals Inc. has established a program to repurpose a psychedelic compound, DMT, for stroke. . .the company is to continue a number of preclinical studies with DMT for stroke and is looking to file an investigational new drug application with the U.S. Food and Drug Administration based on DMT's historical data of Phase 1 clinical trials and new preclinical data generated by Algernon."

Clive Maund, CliveMaund.com

(2/1/21)
"Algernon Pharmaceuticals Inc. is looking like a Buy again here as it is at the bottom of the shallow uptrend that has developed from the December low, and a stop may be placed beneath the lower rail of the channel. An additional reason for buying the company here that may lead to a bigger move is the good news out of it this morning that it is commencing clinical research with a psychedelic drug for stroke treatment."

Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2.
read more >
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials.
read more >
Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil.
read more >

Clive Maund, CliveMaund.com

(12/28/20)
"The good news with Algernon Pharmaceuticals Inc. is that the stock has now arrived at a much stronger long-term support level in a deeply oversold state, so the least we can expect is a significant bounce from here. On Thursday there was a moderately bullish candle on strong volume with it closing well off the lows, which suggests that it may be reversing here or at least have hit bottom."

Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial.
read more >
Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report.
read more >
Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators.
read more >
headshot of André Uddin

André Uddin, Research Capital Corporation

(12/15/20)
"Algernon Pharmaceuticals Inc. reports interim results of a COVID-19 Phase 2b/3 trial with Ifenprodil. . .The results showed two positive early trends in high-dose ifenprodil at Day 15: (i) fewer patients required mechanical ventilation and (ii) the reduction of the NEWS score (used to monitor patient status) was quicker, which could potentially translate to a faster recovery down the road. . .We are maintaining our SPECULATIVE BUY rating and TP of $0.80/share. AGN remains a high risk high reward investment opportunity."

Clive Maund, CliveMaund.com

(12/8/20)
"Algernon Pharmaceuticals Inc. is now in a vigorous uptrend. It has paused for a rest in recent days with a small bull Pennant believed to be forming. Current light volume and strong Accumulation line suggest that another upleg is imminent."

Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition.
read more >
Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020.
read more >
Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy.
read more >

More Expert Comments

Experts Following This Company

Knox Henderson
Dr. KSS, Founder and Editor-in-Chief – BioPub.co
Clive Maund – CliveMaund.com
headshot of André Uddin
André Uddin – Research Capital Corporation

Company News

4/8/2021 – Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

4/6/2021 – Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

3/31/2021 – Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

3/29/2021 – Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

3/17/2021 – Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

3/11/2021 – Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil

3/5/2021 – Algernon Pharmaceuticals Announces Increase and Close of Private Placement

3/3/2021 – Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

3/1/2021 – Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

3/1/2021 – Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer

2/19/2021 – Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

2/17/2021 – Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data

2/10/2021 – Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

2/8/2021 – Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

2/3/2021 – Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

2/1/2021 – Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"

1/22/2021 – Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Advancing new drug treatments for billion dollar global disease markets.
 
Conducting multiple phase II clinical trials
 
Experienced management team & globally recognized medical advisory board
catalyst Calendar
Q2
2021
U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4
2021
Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4
2021
Phase 1 Study planned for DMT, Q4 2021
Algernon Pharmaceuticals Inc. Content